Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CG-BM1 in Sarcopenia
NCT07865676Phase 2Recruiting
- Sponsor
- Guangzhou Saijun Biotechnology Co., Ltd.
- Start
- Apr 2026
- Primary completion
- Jun 2029
- Countries
- 1
01
Overview
Phase 2, open-label trial of CG-BM1 in Sarcopenia (2 arms), sponsored by Guangzhou Saijun Biotechnology Co., Ltd. Primary endpoint: Incidence of study-related adverse events and serious adverse events. Started Apr 2026; status: recruiting.
02
Drugs
CG-BM1
03
Conditions
Sarcopenia
Beyond the preview
Go deeper on NCT07865676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07865676.